| Project/Area Number |
15K18970
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
General physiology
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
ZHANG Ying 山口大学, 大学院医学系研究科, 助教 (10711260)
|
|---|
| Research Collaborator |
KOBAYASHI Sei 山口大学, 大学院医学系研究科, 教授
KISHI Hiroko 山口大学, 大学院医学系研究科, 准教授
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 血管攣縮 / paxillin / Fyn / Rho-kinase / 血管病 / 血管平滑筋 / 異常収縮 / 分子間相互作用 / Ｆｙｎ |
|---|
| Outline of Final Research Achievements |
Vascular abnormal contraction, known as vasospasm, including cardiovascular and cerebrovascular vasospasm, remains a significant source of morbidity and mortality in sudden death and in patients after subarachnoid hemorrhage. We previously demonstrated that sphingosylphosphorylcholine (SPC) induced this abnormal vascular contraction via a SPC/Fyn/Rho-kinase(ROK) signalling pathway. However, molecular mechanisms between Fyn and ROK remain unclear. In the present study, we identified paxillin as a novel signalling molecule acting downstream of Fyn. Our results indicate that paxillin may be a new therapeutic target for vascular abnormal contraction.
|
